viewAnteris Technologies Ltd

Admedus has capital raising news imminent, granted ASX trading halt

The halt will remain in place until the start of trade on August 6 or earlier if an announcement is released.

ASX sign
Admedus’ medical technologies are aimed at creating life-changing outcomes

Admedus Ltd (ASX:AHZ) has been granted a trading halt by the ASX pending news of a capital raising.

The halt will remain in place until the start of trade on ASX on Monday, August 6, or earlier if an announcement is released to the market.

Shares last traded at 13.5 cents before the halt.

READ: Admedus commences animal trials for heart valve device

During July the company released news regarding progress with its patented transcatheter aortic valve replacement (TAVR) project and its ADAPT® technology.

Admedus has commenced animal trials by completing the first successful live implantation of its unique single-piece aortic heart valve, representing a key milestone in development of the TAVR project.

Five-month trial

The company has partnered with a European lab to examine the safety and feasibility of the unique valve in live sheep.

Implanting of the first single-piece valve officially marked the start of the trial period, which is expected to last for around five months.

READ: Admedus signs exclusive distribution agreement in Italy for its unique heart tissue product

Earlier in July, the company signed an exclusive distribution agreement with Medical Instruments S.p.A. to market and distribute its clinically-superior ADAPT® technology in Italy.

Under the agreement, Medical Instruments will initially distribute Admedus’ non-toxic and non-calcifying flagship ADAPT bio-scaffold CardioCel®.

The bio-scaffold is used to repair congenital heart deformities and more complex heart defects.

It is also used to reconstruct dysfunctional heart valves and valve leaflets.

Quick facts: Anteris Technologies Ltd

Price: 3.72 AUD

Market: ASX
Market Cap: $21.99 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Anteris Technologies Ltd named herein, including the promotion by the Company of Anteris Technologies Ltd in any Content on the Site, the...


Admedus CEO in New York to update on recent key milestones

Admedus Ltd (ASX:AHZ) CEO Wayne Paterson visited the Proactive Investors New York studio to update on key milestones the company has achieved in the past few months, including receiving European approval on two of its products.

on 03/17/2019

2 min read